O
Olga Frankfurt
Researcher at Northwestern University
Publications - 115
Citations - 4106
Olga Frankfurt is an academic researcher from Northwestern University. The author has contributed to research in topics: Myeloid leukemia & Transplantation. The author has an hindex of 26, co-authored 107 publications receiving 3157 citations.
Papers
More filters
Journal ArticleDOI
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
Courtney D. DiNardo,Keith W. Pratz,Vinod Pullarkat,Brian A. Jonas,Martha Arellano,Pamela S. Becker,Pamela S. Becker,Olga Frankfurt,Marina Konopleva,Andrew H. Wei,Hagop M. Kantarjian,Tu Xu,Wan Jen Hong,Brenda Chyla,Jalaja Potluri,Daniel A. Pollyea,Anthony Letai +16 more
TL;DR: The novel combination of venetoclax with decitabine or azacitidine was effective and well tolerated in elderly patients with AML and achieved complete remission (CR) + CR with incomplete count recovery (CRi).
Journal ArticleDOI
Myelodysplastic syndromes, version 2.2017: Clinical practice guidelines in oncology
Peter L. Greenberg,Richard Stone,Aref Al-Kali,Stefan K. Barta,Rafael Bejar,John M. Bennett,Hetty E. Carraway,Carlos M. de Castro,H. Joachim Deeg,Amy E. DeZern,Amir T. Fathi,Olga Frankfurt,Karin M.L. Gaensler,Guillermo Garcia-Manero,Elizabeth A. Griffiths,David R. Head,Ruth Horsfall,Robert A. Johnson,Mark B. Juckett,Virginia M. Klimek,Rami S. Komrokji,Lisa Kujawski,Lori J. Maness,Margaret R. O'Donnell,Daniel A. Pollyea,Paul J. Shami,Brady L. Stein,Alison Walker,Peter Westervelt,Amer M. Zeidan,Dorothy A. Shead,Courtney Smith +31 more
TL;DR: This portion of the guidelines focuses on diagnostic classification, molecular abnormalities, therapeutic options, and recommended treatment approaches for myelodysplastic syndromes.
Journal ArticleDOI
Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole
Steven Trifilio,Seema Singhal,Stephanie F. Williams,Olga Frankfurt,Leo I. Gordon,Andrew M. Evens,Jane N. Winter,Martin S. Tallman,J. Pi,Jayesh Mehta +9 more
TL;DR: Voriconazole is effective at preventing aspergillosis, however, breakthrough zygomycosis is seen in a small proportion of patients, and the role of therapeutic voriconzole monitoring with dose adjustment to avoid breakthrough infections with fungi that are otherwise susceptible to the drug needs to be explored prospectively.
Journal ArticleDOI
Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients.
Steve Trifilio,Gennethel Pennick,J. Pi,J. Zook,M. Golf,Kimberley Kaniecki,Seema Singhal,Stephanie F. Williams,Jane N. Winter,Martin S. Tallman,Leo I. Gordon,Olga Frankfurt,Andrew M. Evens,Jayesh Mehta +13 more
TL;DR: Low voriconazole levels have been associated with a higher failure rate in patients with confirmed fungal infections and should be considered a cause for concern.
Journal ArticleDOI
Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.
Arthur E. Frankel,Jung H. Woo,Chul Ahn,Naveen Pemmaraju,Bruno C. Medeiros,Hetty E. Carraway,Olga Frankfurt,Stephen J. Forman,Xuezhong A. Yang,Marina Konopleva,Francine Garnache-Ottou,Fanny Angelot-Delettre,Christopher L. Brooks,Michael Szarek,Eric K. Rowinsky +14 more
TL;DR: The activity of SL-401, diptheria toxin (DT)388IL3 composed of the catalytic and translocation domains of DT fused to IL3, was evaluated in BPD CN patients in a phase 1-2 study and seven of 9 evaluable BPDCN patients had major responses including 5 complete responses and 2 partial responses after a single course ofSL-401.